IL2 and cancer: MMPs broke down interleukin-2-α (IL-2Rα) receptor on T-lymphocytes, which in turn inhibit T-lymphocytes proliferation; releasing TGF-β, which is an important suppressor of T-cell reaction against cancer cell; cleave α1-proteinase inhibitor (α1-PI), decreasing cancer sensitivity toward natural killer cells; and split CC and CXC chemokine family, that help cancer cells slip away from leukocytes.